Evaxion A/S (EVAX) & Its Competitors Head to Head Analysis

Evaxion A/S (NASDAQ:EVAX – Get Free Report) is one of 843 public companies in the “Biotechnology” industry, but how does it weigh in compared to its peers? We will compare Evaxion A/S to related businesses based on the strength of its dividends, profitability, risk, earnings, institutional ownership, valuation and analyst recommendations.

Volatility and Risk

Evaxion A/S has a beta of 0.6, meaning that its share price is 40% less volatile than the S&P 500. Comparatively, Evaxion A/S’s peers have a beta of -1.84, meaning that their average share price is 284% less volatile than the S&P 500.

Earnings and Valuation

This table compares Evaxion A/S and its peers gross revenue, earnings per share and valuation.

Gross Revenue Net Income Price/Earnings Ratio
Evaxion A/S $7.53 million -$7.71 million -2.30
Evaxion A/S Competitors $688.58 million $7.69 million -18.30

Evaxion A/S’s peers have higher revenue and earnings than Evaxion A/S. Evaxion A/S is trading at a higher price-to-earnings ratio than its peers, indicating that it is currently more expensive than other companies in its industry.

Profitability

This table compares Evaxion A/S and its peers’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Evaxion A/S N/A -61.43% -34.23%
Evaxion A/S Competitors -12,224.75% -204.85% -31.52%

Institutional and Insider Ownership

11.0% of Evaxion A/S shares are held by institutional investors. Comparatively, 47.8% of shares of all “Biotechnology” companies are held by institutional investors. 41.6% of Evaxion A/S shares are held by insiders. Comparatively, 13.1% of shares of all “Biotechnology” companies are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Analyst Ratings

This is a breakdown of recent ratings and target prices for Evaxion A/S and its peers, as reported by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Evaxion A/S 1 0 4 0 2.60
Evaxion A/S Competitors 9941 15328 45742 1605 2.54

Evaxion A/S currently has a consensus price target of $11.25, suggesting a potential upside of 304.68%. As a group, “Biotechnology” companies have a potential upside of 133.42%. Given Evaxion A/S’s stronger consensus rating and higher possible upside, equities analysts clearly believe Evaxion A/S is more favorable than its peers.

Summary

Evaxion A/S beats its peers on 8 of the 13 factors compared.

Evaxion A/S Company Profile

(Get Free Report)

Evaxion A/S is a Denmark-based biotechnology company that uses artificial intelligence to discover and develop immunotherapies and vaccines. Its research focuses on treatments for cancer and infectious diseases, with the goal of identifying targets that can prompt the immune system to recognize and attack disease. The company’s pipeline includes personalized cancer immunotherapy candidates, including EVX-01, as well as vaccine programs for cancer and infectious diseases. Evaxion uses proprietary AI platforms to analyze biological data and identify potential targets for these programs.

Receive News & Ratings for Evaxion A/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Evaxion A/S and related companies with MarketBeat.com's FREE daily email newsletter.